- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S8563
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Fatty Acid Synthase Inhibitors | Denifanstat (TVB-2640) Betulin FT113 Fatostatin C75 C75 trans Desoxyrhaponticin trans-Chalcone IPI-9119 Eicosapentaenoic acid ethyl ester |
|
In vitro |
DMSO
: 94 mg/mL
(200.65 mM)
Ethanol : 50 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 468.47 | Formula | C25H23F3N4O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2097262-58-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=CC(=C(C=C1C2=C(NC(=N2)C(F)(F)F)COC)C(=O)N3CC(C3)C4=CC=C(C=C4)C#N)C | ||
| Targets/IC50/Ki |
FASN
(mouse cell palmitate synthesis) 0.012 μM
FASN
(human cell palmitate synthesis) 0.018 μM
|
|---|---|
| In vitro |
TVB-3664 induces FASN inhibition with significantly reduced tubulin palmitoylation and mRNA expression. Disrupted microtubule organization in tumor cells is an additional consequence of FASN inhibition. This compound combined with taxane treatment enhances inhibition of in vitro tumor cell growth compared to treatmentwith either agent alone. |
| In vivo |
In lung, ovarian, prostate, and pancreatic tumor xenograft studies, TVB-3664 inhibit xenograft tumor growth with significantly enhanced anti-tumor activity. Tumor regression is observed in 3 of 6 tumor xenograftmodels. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.